MarketCapExport financials
Arcadia Biosciences (RKDA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Arcadia Biosciences Balance Sheet 2025-2011 | RKDA
Brief overview of Arcadia Biosciences's financial position
This overview follows the five latest available annual observations between 2021 and 2025.
Across five reporting periods, assets decreased -85.1%, from $43.9 million to $6.5 million, producing a negative trend.
Asset growth of -85.1% was close to the -81.1% change in liabilities, leaving the funding profile broadly stable.
Equity funds 63.2% of assets versus 70.8% initially. This creates a conservative balance sheet structure.
Cash represents 4% of assets versus 65.3% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$281.2 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Arcadia Biosciences's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Arcadia Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -5.51 M | -18.6 M | -25.4 M | -10.8 M | -8.29 M | -12 M | -9.12 M | 71.7 M | 27.2 M | -2.1 M | 11.7 M | 2.65 M | - |
Long Term Debt |
- | - | 155 K | 1.01 M | 2.22 M | 2.1 M | 107 K | - | - | 25.1 M | 24.9 M | 8.87 M | 9.92 M | 8 M | - |
Long Term Debt Current |
- | 155 K | 852 K | 1.01 M | 1.07 M | 717 K | 611 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 12.5 M | 18.5 M | 8.16 M | 5.04 M | 31.2 M | 30.6 M | 15.5 M | 17.3 M | 15.7 M | - |
Total Current Liabilities |
2.06 M | 2.56 M | 3.59 M | 4.21 M | 5.04 M | 6.31 M | 5.71 M | 3.05 M | 3.52 M | 3.13 M | 3.45 M | - | - | - | - |
Total Liabilities |
2.41 M | 7.29 M | 7 M | 8.02 M | 12.7 M | 18.8 M | 24.2 M | 11.2 M | 8.56 M | 34.4 M | 34 M | 26.8 M | 26.8 M | 19 M | - |
Deferred Revenue |
- | - | - | - | - | 8 K | 42 K | 96 K | 1 M | 740 K | 1.01 M | 830 K | 1.07 M | 1.16 M | - |
Retained Earnings |
-281 M | -279 M | -272 M | -258 M | -226 M | -212 M | -207 M | -178 M | -167 M | -152 M | -132 M | -114 M | -95.6 M | -82.4 M | - |
Total Assets |
6.55 M | 13.5 M | 19.7 M | 28.9 M | 43.9 M | 47.3 M | 32.6 M | 24 M | 16.6 M | 56.6 M | 74.2 M | 24.9 M | 9.54 M | 13.4 M | - |
Cash and Cash Equivalents |
259 K | 4.24 M | 6.52 M | 20.6 M | 28.7 M | 14 M | 8.42 M | 12 M | 9.12 M | 2.01 M | 24 M | 16.6 M | - | - | - |
Book Value |
4.14 M | 6.22 M | 12.7 M | 20.9 M | 31.2 M | 28.6 M | 8.33 M | 12.8 M | 8.01 M | 22.2 M | 40.2 M | -1.88 M | -17.3 M | -5.68 M | - |
Total Shareholders Equity |
4.14 M | 6.22 M | 12.8 M | 21 M | 31.1 M | 27.7 M | 7.7 M | 12.8 M | 8.01 M | 22.2 M | 40.2 M | -84.8 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Arcadia Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | 11 K | 21 K | 155 K | 347 K | 532 K | 760 K | 1.01 M | 1.27 M | 1.5 M | 1.71 M | 2.22 M | 78 K | 87 K | 96 K | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 107 K | 107 K | 107 K | 1.5 M | - | - | - | - | - | - | 21.1 M | 23.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 8.87 M | 8.87 M | 8.87 M | 8.87 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.7 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.41 M | 2.44 M | 7.29 M | 3.14 M | 3.26 M | 4.08 M | 7.29 M | 5.09 M | 5.8 M | 5.56 M | 7 M | 8.07 M | 9.07 M | 13.7 M | 8.02 M | 9.46 M | 8.24 M | 8.56 M | 12.7 M | 19 M | 28.1 M | 25.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 8.56 M | 8.56 M | 8.56 M | 8.56 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 34 M | 34 M | 34 M | 34 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63 K | 63 K | 8 K | 8 K | 8 K | 8 K | 42 K | 42 K | 42 K | 42 K | 96 K | 316 K | 470 K | 571 K | 1 M | 626 K | 1 M | 1 M | 740 K | 740 K | 740 K | 740 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 830 K | 830 K | 830 K | 830 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-281 M | -286 M | -279 M | -280 M | -281 M | -276 M | -279 M | -275 M | -273 M | -274 M | -272 M | -269 M | -266 M | -267 M | -258 M | -254 M | -251 M | -247 M | -226 M | -217 M | -215 M | -210 M | -212 M | -212 M | -212 M | -212 M | -207 M | -207 M | -207 M | -207 M | -178 M | -178 M | -178 M | -178 M | -167 M | -167 M | -167 M | -167 M | -152 M | -152 M | -152 M | -152 M | -132 M | -132 M | -132 M | -132 M | -114 M | -114 M | -114 M | -114 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
6.55 M | 5.32 M | 13.5 M | 8.58 M | 7.79 M | 13 M | 13.5 M | 15.2 M | 17.4 M | 16 M | 19.7 M | 23.5 M | 26.8 M | 30.4 M | 28.9 M | 34.5 M | 35 M | 38.8 M | 43.9 M | 59.2 M | 70.8 M | 70.8 M | 47.3 M | 47.3 M | 47.3 M | 47.3 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | 24 M | 24 M | 24 M | 24 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 56.6 M | 56.6 M | 56.6 M | 56.6 M | 74.2 M | 74.2 M | 74.2 M | 74.2 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
259 K | 954 K | 4.24 M | 1.12 M | 1.38 M | 3.16 M | 4.24 M | 3.94 M | 5.5 M | 3.32 M | 6.52 M | 10.6 M | 13.5 M | 23 M | 20.6 M | 22.7 M | 21.2 M | 24.6 M | 28.7 M | 35.5 M | 44 M | 32.8 M | 14 M | 14 M | 14 M | 14 M | 8.42 M | 8.42 M | 8.42 M | 8.42 M | 12 M | 12 M | 12 M | 12 M | 9.12 M | 9.12 M | 9.12 M | 9.12 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 24 M | 24 M | 24 M | 24 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 2.84 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
4.14 M | 2.88 M | 6.22 M | 5.44 M | 4.53 M | 8.9 M | 6.22 M | 10.1 M | 11.6 M | 10.5 M | 12.7 M | 15.4 M | 17.7 M | 16.7 M | 20.9 M | 25 M | 26.8 M | 30.2 M | 31.2 M | 40.2 M | 42.7 M | 45.7 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 8.01 M | 8.01 M | 8.01 M | 8.01 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | -1.88 M | -1.88 M | -1.88 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
6.22 M | 2.88 M | 12.7 M | 5.44 M | 4.53 M | 8.9 M | 6.22 M | 10.1 M | 11.6 M | 10.5 M | 12.8 M | 15.4 M | 17.7 M | 16.7 M | 21 M | 25 M | 26.8 M | 30.2 M | 31.1 M | 40.2 M | 42.7 M | 45.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 8.01 M | 8.01 M | 8.01 M | 8.01 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | -84.8 M | -84.8 M | -84.8 M | -84.8 M | -17.3 M | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Arcadia Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Agricultural inputs
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CF Industries Holdings
CF
|
$ 122.16 | 2.41 % | $ 19.8 B |  USA |
 |
The Mosaic Company
MOS
|
$ 22.88 | 0.46 % | $ 7.26 B | USA |
 |
Corteva
CTVA
|
$ 12.17 | 0.5 % | $ 8.28 B | USA |
 |
Nutrien Ltd.
NTR
|
$ 72.18 | -0.15 % | $ 35.1 B |  Canada |
 |
Акрон
AKRN
|
- | - | - |  Russia |
 |
ФосАгро
PHOR
|
- | - | - | Russia |
 |
Yield10 Bioscience
YTEN
|
- | 15.32 % | $ 46.6 M | USA |
 |
Origin Agritech Limited
SEED
|
$ 0.68 | 3.88 % | $ 5.09 M |  China |
 |
Marrone Bio Innovations
MBII
|
- | -5.9 % | $ 180 M | USA |
 |
Bioceres Crop Solutions Corp.
BIOX
|
$ 0.21 | -9.65 % | $ 13.3 M |  Argentina |
 |
American Vanguard Corporation
AVD
|
$ 0.83 | 1.21 % | $ 23.6 M | USA |
 |
ICL Group Ltd
ICL
|
$ 4.68 | -1.07 % | $ 6.04 B |  Israel |
 |
Intrepid Potash
IPI
|
$ 33.42 | 0.48 % | $ 435 M | USA |
 |
FMC Corporation
FMC
|
$ 5.65 | 4.34 % | $ 707 M | USA |
 |
The Scotts Miracle-Gro Company
SMG
|
$ 65.1 | -1.87 % | $ 3.75 B | USA |
 |
CVR Partners, LP
UAN
|
$ 111.9 | 0.48 % | $ 1.18 B | USA |
 |
China Green Agriculture
CGA
|
- | 0.51 % | $ 27.6 M | China |